The Senate Committee on Health, Education, Labor and Pensions holds a hearing on why Novo Nordisk is charging Americans with diabetes and obesity high prices for Ozempic and Wegovy. Novo Nordisk CEO Lars Fruergaard Jorgensen testifies at the hearing.
|
|
|
